Investigation of structure and function of a catalytically efficient variant of the human flavin-containing monooxygenase form 3

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 1995-2002

  Borbás, Tímea ^b   Zhang, Jun ^a   Cerny, Matt A ^a   Likó, István ^b   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

10 [(N,N, DIMETHYLAMINOPENTYL) 2 (TRIFLUOROMETHYL)]PHENOTHIAZINE; CHLORPROMAZINE; DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 1; FLAVIN CONTAINING MONOOXYGENASE 3; IMIDAZOLE DERIVATIVE; MERCAPTOIMIDAZOLE; PHENOTHIAZINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; MOLECULAR MODEL; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; SITE DIRECTED MUTAGENESIS; THERMOSTABILITY;

AMINO ACID SUBSTITUTION; CHLORPROMAZINE; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; OXYGENASES; PHENOTHIAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33751535481     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010827     Document Type: Article

References (46)

1. Akerman BR, Forrest S, Chow L, Youil R, Knight M, and Treacy EP (1999) Two mutations of the FMO3 gene in a proband with trimethylaminuria. Hum Mutat 13:376-379.
2. Ballou DP, Entsch B, and Cole LJ (2005) Dynamics involved in catalysis by single-component and two-component flavin-dependent aromatic hydroxylases. Biochem Biophys Res Commun 338:590-598.
3. Beaty N and Ballou D (1980) A kinetic investigation of liver microsomal mixed function amine oxidase, in Microsomes, Drug Oxidation and Chemical Carcinogenesis, (Coon MJ, Conney AH, Estabrook RW, Gelboin HV, Gillette JR, and O'Brien PJ eds) pp 209-302, Academic Press, New York.
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235-242.
5. Brunelle A, Bi YA, Lin J, Russell B, Luy L, Berkman C, and Cashman J (1997) Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions. Drug Metab Dispos 25:1001-1007.
6. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
7. Cashman JR (2002a) Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3:325-339.
8. Cashman JR (2002b) Flavin monooxygenases, in Enzyme Systems that Metabolize Drugs and Other Xenobiotics (Ioannides C ed) pp 67-94, John Wiley and Sons, Ltd., London.
9. Cashman JR, Camp K, Fakharzadeh SS, Fennessey PV, Hines RN, Mamer OA, Mitchell SC, Schlenk D, Smith RL, Tjoa SS, et al. (2003) Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr Drug Metab 4:151-170.
10. Cashman JR and Zhang J (2002) Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos 30:1043-1052.
11. Cashman JR and Zhang J (2006) Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65-100.
12. Cashman JR, Zhang J, Leushner J, and Braun A (2001) Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab Dispos 29:1629-1637.
13. Dixit A and Roche TE (1984) Spectrophotometric assay of the flavin-containing monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. Arch Biochem Biophys 233:50-63.
14. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (1997) Missense mutation in flavin-containing monooxygenase 3 gene, underlies fish-odour syndrome. Nat Genet 17:491-494.
15. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (2000) Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. Pharmacogenetics 20:799-807.
16. Eswaramoorthy S, Bonanno JB, Burley SK, and Swaminathan S (2006) Mechanism of action of a flavin-containing monooxygenase. Proc Natl Acad Sci USA 103:9832-9837.
17. Furnes B, Feng J, Sommer S, and Schlenk D (2003) Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos 31:187-193.
18. Guex N and Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723.
19. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, and Hall SD (2000) Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol 60:7-17.
20. Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse; identification of novel gene pseudogene clusters. Pharmacogenetics 14:117-130.
21. Hines RN, Hopp KA, Fanco J, Saeian K, and Begun FP (2002) Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 62:320-325.
22. Hisamuddin IM, Whebi MA, Chao A, Wyre HW, Hylind LM, Giardiello FM, and Yang VW (2004) Genetic polymorphisms of human flavin-containing monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res 10:8357-8362.
23. Kang JH, Chung WG, Lee KH, Park CS, Kang JS, Shin IC, Roh HK, Dong MS, Baek HM, and Cha YN (2000) Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics 10:67-78.
24. Koukouritaki SB and Hines RN (2005) Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 8:807-822.
25. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, and Hines RN (2005) Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol Pharmacol 68:383-392.
26. Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms, and role in drug metabolism. Pharmacol Ther 106:357-387.
27. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
28. Lattard V, Zhang J, and Cashman JR (2004) Alternative processing events in human FMO genes. Mol Pharmacol 65:1517-1525.
29. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 31:854-860.
30. Lawton M, Cashman J, Cresteil T, Dolphin C, Elfarra A, Hines RN, Hodgson E, Kimura T, Ozols J, Phillips IR, et al. (1994) A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identity. Arch Biochem Biophys 308:254-257.
31. Lomri N, Gu Q, and Cashman JR (1992) Molecular cloning of flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc Natl Acad Sci USA 89:1685-1689.
32. Lomri N, Yang Z, and Cashman JR (1993) Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. Chem Res Toxicol 6:425-429.
33. Malito E, Alfieri A, Fraaije MW, and Mattevi A (2004) Crystal structure of a Baeyer-Villiger monooxygenase. Proc Natl Acad Sci USA 101:13157-13162.
34. Mayatepek E, Flock B, and Zschocke J (2004) Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics 14:775-777.
35. Mitchell SC, Zhang AQ, Barrett T, Ayesh R, and Smith RL (1997) Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populations. Pharmacogenetics 7:45-50.
36. Mittl PRE, Berry A, Scrutton NS, Perham RN, and Schulz GE (1994) Anatomy of an engineered NAD-binding site. Protein Sci 9:1504-1514.
37. Park CS, Kang JH, Chung WG, Yi HG, Pie JE, Park DK, Hines RN, McCarver DG, and Cha YN (2002) Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12:77-80.
38. Peitsch MC (1995) Protein modeling by email. Bio/Technology 13:658-660.
39. Poulsen LL and Ziegler DM (1979) The liver microsomal FAD-containing monooxygenase: spectral characterization and kinetic studies. J Biol Chem 254:6449-6455.
40. Schwede T, Kopp J, Guex N, and Peitsch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31:3381-3385.
41. Stehle T, Ahmed SA, Claiborne A, and Schulz GE (1991) Structure of NADH peroxidase from Streptococcus faecalis 10C1 refined at 2.16 angstroms resolution. J Mol Biol 221:1325-1330.
42. Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J, Bruce AG, Knight M, Danks DM, Cashman JR, et al. (1998) Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 7:839-845.
43. Wyatt MK, Overby LH, Lawton MP, and Philpot RM (1998) Identification of amino acid residues associated with modulation of flavin-containing monooxygenase (FMO) activity by imipramine: structure/function studies with FMO1 from pig and rabbit. Biochemistry 37:5930-5938.
44. Zhang J and Cashman JR (2006) Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 34:19-26.
45. Ziegler DM (1988) Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab Rev 19:1-32.
46. Ziegler DM (2002) An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab Rev 34:503-511.